{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:24:26Z","timestamp":1760217866267,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370643","81470305","81670124"],"award-info":[{"award-number":["81370643","81470305","81670124"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Provincial Key Innovation Team","award":["2011R50015"],"award-info":[{"award-number":["2011R50015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00432-017-2570-8","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T05:15:56Z","timestamp":1517462156000},"page":"697-706","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma"],"prefix":"10.1007","volume":"144","author":[{"given":"Xiao","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yile","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiansong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingrui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenglin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-9915","authenticated-orcid":false,"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,1]]},"reference":[{"issue":"12","key":"2570_CR1","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/ijc.29326","volume":"136","author":"S Bernard","year":"2015","unstructured":"Bernard S, Danglade D, Gardano L, Laguillier C, Lazarian G, Roger C, Thieblemont C, Marzec J, Gribben J, Cymbalista F, Varin-Blank N, Ledoux D, Baran-Marszak F (2015) Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. Int J Cancer 136(12):2761\u20132774","journal-title":"Int J Cancer"},{"issue":"2","key":"2570_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3109\/08830185.2012.664797","volume":"31","author":"JJ Buggy","year":"2012","unstructured":"Buggy JJ, Elias L (2012) Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 31(2):119\u2013132","journal-title":"Int Rev Immunol"},{"issue":"14","key":"2570_CR3","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","volume":"122","author":"BY Chang","year":"2013","unstructured":"Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM, Kuil A, Herman SE, Chang S, Pals ST, Wilson W, Wiestner A, Spaargaren M, Buggy JJ, Elias L (2013) Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor Ibrutinib in mantle cell lymphoma patients. Blood 122(14):2412\u20132424","journal-title":"Blood"},{"issue":"10","key":"2570_CR4","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","volume":"37","author":"M Cinar","year":"2013","unstructured":"Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S (2013) Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res 37(10):1271\u20131277","journal-title":"Leuk Res"},{"issue":"1","key":"2570_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/hmg\/3.1.161","volume":"3","author":"M Weers de","year":"1994","unstructured":"de Weers M, Mensink RG, Kraakman ME, Schuurman RK, Hendriks RW (1994) Mutation analysis of the Bruton\u2019s tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice. Hum Mol Genet 3(1):161\u2013166","journal-title":"Hum Mol Genet"},{"issue":"16","key":"2570_CR6","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","volume":"21","author":"RA Claro de","year":"2015","unstructured":"de Claro RA, McGinn KM, Verdun N, Lee SL, Chiu HJ, Saber H, Brower ME, Chang CJ, Pfuma E, Habtemariam B, Bullock J, Wang Y, Nie L, Chen XH, Lu DR, Al-Hakim A, Kane RC, Kaminskas E, Justice R, Farrell AT, Pazdur R (2015) FDA Approval: Ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia. Clin Cancer Res 21(16):3586\u20133590","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2570_CR7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9(8):550\u2013562","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"2570_CR8","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","volume":"123","author":"SE Herman","year":"2014","unstructured":"Herman SE, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, Farooqui M, Wiestner A (2014) Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood 123(21):3286\u20133295","journal-title":"Blood"},{"issue":"29","key":"2570_CR9","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107(29):13075\u201313080","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2570_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/17474086.2017.1318053","volume":"10","author":"M Jiang","year":"2017","unstructured":"Jiang M, Bennani NN, Feldman AL (2017) Lymphoma classification update: B-cell non-Hodgkin lymphomas. Expert Rev Hematol 10(5):405\u2013415","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"2570_CR11","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00277-017-2973-2","volume":"96","author":"V Kaur","year":"2017","unstructured":"Kaur V, Swami A (2017) Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond Ibrutinib. Ann Hematol 96(7):1175\u20131184","journal-title":"Ann Hematol"},{"issue":"38","key":"2570_CR12","doi-asserted-by":"publisher","first-page":"13906","DOI":"10.1073\/pnas.1409362111","volume":"111","author":"NL Komarova","year":"2014","unstructured":"Komarova NL, Burger JA, Wodarz D (2014) Evolution of Ibrutinib resistance in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci USA 111(38):13906\u201313911","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2570_CR13","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/bjh.12974","volume":"166","author":"J Ma","year":"2014","unstructured":"Ma J, Lu P, Guo A, Cheng S, Zong H, Martin P, Coleman M, Wang YL (2014) Characterization of Ibrutinib-sensitive and -resistant mantle lymphoma cells. Br J Haematol 166(6):849\u2013861","journal-title":"Br J Haematol"},{"issue":"7","key":"2570_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1440-1827.1997.tb04519.x","volume":"47","author":"S Nakamura","year":"1997","unstructured":"Nakamura S, Yatabe Y, Seto M (1997) Cyclin D1 over expression in malignant lymphomas. Pathol Int 47(7):421\u2013429","journal-title":"Pathol Int"},{"issue":"1","key":"2570_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/cmdc.200600221","volume":"2","author":"Z Pan","year":"2007","unstructured":"Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT (2007) Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase. Chem Med Chem 2(1):58\u201361","journal-title":"Chem Med Chem"},{"issue":"1","key":"2570_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","volume":"117","author":"P Perez-Galan","year":"2011","unstructured":"Perez-Galan P, Dreyling M, Wiestner A (2011) Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 117(1):26\u201338","journal-title":"Blood"},{"issue":"1","key":"2570_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/1042819031000151112","volume":"45","author":"MJ Rummel","year":"2004","unstructured":"Rummel MJ, de Vos S, Hoelzer D, Koeffler HP, Hofmann WK (2004) Altered apoptosis pathways in mantle cell lymphoma. Leuk Lymphoma 45(1):49\u201354","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2570_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4049\/jimmunol.182.1.329","volume":"182","author":"S Sharma","year":"2009","unstructured":"Sharma S, Orlowski G, Song W (2009) Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells. J Immunol 182(1):329\u2013339","journal-title":"J Immunol"},{"issue":"20","key":"2570_CR19","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390","journal-title":"Blood"},{"issue":"2","key":"2570_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","volume":"72","author":"S Tsukada","year":"1993","unstructured":"Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, Sparkes RS, Kubagawa H, Mohandas T, Quan S et al (1993) Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72(2):279\u2013290","journal-title":"Cell"},{"issue":"8","key":"2570_CR21","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ajh.24797","volume":"92","author":"JM Vose","year":"2017","unstructured":"Vose JM (2017) Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am J Hematol 92(8):806\u2013813","journal-title":"Am J Hematol"},{"issue":"6","key":"2570_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA (2013) Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507\u2013516","journal-title":"N Engl J Med"},{"issue":"3","key":"2570_CR23","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1053\/j.seminhematol.2011.05.001","volume":"48","author":"MA Weniger","year":"2011","unstructured":"Weniger MA, Wiestner A (2011) Molecular targeted approaches in mantle cell lymphoma. Semin Hematol 48(3):214\u2013226","journal-title":"Semin Hematol"},{"issue":"1","key":"2570_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1200\/JCO.2012.44.4281","volume":"31","author":"A Wiestner","year":"2013","unstructured":"Wiestner A (2013) Targeting B-Cell receptor signaling for anticancer therapy: the Bruton\u2019s tyrosine kinase inhibitor Ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 31(1):128\u2013130","journal-title":"J Clin Oncol"},{"issue":"8","key":"2570_CR25","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1182\/blood-2013-07-515361","volume":"123","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, MacMurray J, Harrington BK, Davis ME, Gobessi S, Laurenti L, Chang BY, Buggy JJ, Efremov DG, Byrd JC, Johnson AJ (2014a) Bruton\u2019s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood 123(8):1207\u20131213","journal-title":"Blood"},{"issue":"24","key":"2570_CR26","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC (2014b) Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor Ibrutinib. N Engl J Med 370(24):2286\u20132294","journal-title":"N Engl J Med"},{"issue":"11","key":"2570_CR27","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1158\/1535-7163.MCT-16-0281","volume":"15","author":"X Xu","year":"2016","unstructured":"Xu X, Mao L, Xu W, Tang W, Zhang X, Xi B, Xu R, Fang X, Liu J, Fang C, Zhao L, Wang X, Jiang J, Hu P, Zhao H, Zhang L (2016) AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patients. Mol Cancer Ther 15(11):2586\u20132597","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2570_CR28","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nrd3937","volume":"12","author":"RM Young","year":"2013","unstructured":"Young RM, Staudt LM (2013) Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 12(3):229\u2013243","journal-title":"Nat Rev Drug Discov"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-017-2570-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2570-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2570-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T21:43:26Z","timestamp":1548971006000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-017-2570-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,1]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["2570"],"URL":"https:\/\/doi.org\/10.1007\/s00432-017-2570-8","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2018,2,1]]},"assertion":[{"value":"28 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Animal experiment was performed according to the guidelines and SOPs approved by the Department of Science and Technology of Zhejiang Province, China. All procedures performed in studies involving human participants were in accordance with the ethical standards of the ethics committee of the First Affiliated Hospital, Zhejiang University School of Medicine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}